Metastatik mide kanserinde taksan içeren tedaviler ile taksan içermeyen tedavilerin etkinliklerinin karşılaştırılması
Date
2012
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Uludağ Üniversitesi
Abstract
Bu çalışmada metastatik mide kanserli hastalarda taksan içerentedaviler ile taksan içermeyen tedavilerin etkinliklerinin karşılaştırılması amaçlanmıştır.Çalışmaya Uludağ Üniversitesi Tıp Fakültesi Onkoloji Bölümü'ndeOcak 2012-Haziran 2012 tarihleri arasında metastatik mide kanseri nedeniyle takip edilen 146 hasta dahil edildi (E:106, K:40). Çalışmaya dahil edilen hastaların dosyaları retrospektif olarak analiz edildi. Bu hastaların 86'sı taksan içeren 60'ı taksan içermeyen kemoterapi rejimi alan hastalardı. İkigrup kendi arasında progresyona kadar geçen süre, genel sağkalım süresi ve tedaviye yanıt bakımından karşılaştırıldı.Genel sağkalım süresi; taksan alan hastalar için 9,2 ay, taksanalmayan hastalar için 9,9 ay bulundu (p=0,62). Progresyona kadar geçen süre taksan alan hastalar için 9,1 ay, taksan almayan hastalarda 8,7 ay bulundu (p=0,46). Tedaviye yanıt oranları (kısmi yanıt+tam yanıt) taksan alan hastalarda %6 iken taksan almayan hastalarda %7 idi (p=0,14).Bu retrospektif analiz, metastatik mide kanseri tedavisinde taksan içermeyen rejimlerin, taksan içeren rejimler kadar etkili olduğunu göstermiştir.
The aim of our study was comparison of the effects of taxane andnon taxane containing regimens in patients with metastatic gastric cancer.One hundred and forty six patients (106 male and 40 female) withmetastatic gastric cancer who were followed in Uludağ University, School of Medicine, Department of Oncology between January 2002 and June 2012 were included in this study. Patient data were retrospectively analyzed. 86 of 146 patients were treated with taxane-containing chemotherapy regimens, 60patients were treated with non-taxane containing chemotherapy regimens. Two groups were compared in terms of time to progression, overall survival and response (complete and partial) to therapy. Patients treated with taxane containing regimens and non-taxane containing regimens had similar overall survival (9.2 months and 9.9 months respectively, p=0.62), time to progression (9.1 months and 8.7 months respectively, p=0.46), and response rate (6% and 7% respectively, p=0.14).Our study showed that non-taxane based regimens are as efficientas taxane-based regimens.
The aim of our study was comparison of the effects of taxane andnon taxane containing regimens in patients with metastatic gastric cancer.One hundred and forty six patients (106 male and 40 female) withmetastatic gastric cancer who were followed in Uludağ University, School of Medicine, Department of Oncology between January 2002 and June 2012 were included in this study. Patient data were retrospectively analyzed. 86 of 146 patients were treated with taxane-containing chemotherapy regimens, 60patients were treated with non-taxane containing chemotherapy regimens. Two groups were compared in terms of time to progression, overall survival and response (complete and partial) to therapy. Patients treated with taxane containing regimens and non-taxane containing regimens had similar overall survival (9.2 months and 9.9 months respectively, p=0.62), time to progression (9.1 months and 8.7 months respectively, p=0.46), and response rate (6% and 7% respectively, p=0.14).Our study showed that non-taxane based regimens are as efficientas taxane-based regimens.
Description
Keywords
Taksan, Metastatik mide kanseri, Taxane, Metastatic gastric cancer.
Citation
Aksoy, S. (2012). Metastatik mide kanserinde taksan içeren tedaviler ile taksan içermeyen tedavilerin etkinliklerinin karşılaştırılması. Yayınlanmamış uzmanlık tezi. Uludağ Üniversitesi Tıp Fakültesi.